Private company · employee equity guide
What is Generate Biomedicines stock worth?
Estimated share price
Generate Biomedicines has an observed estimated price: most recent data 2026-08-28, daily history back to 2024-06-18.
Estimated from live trades and accepted bids across employer liquidity programs, institutional trades, broker trades, and pre-IPO marketplaces. Private shares are illiquid and transfer-restricted; estimates are educational, not an offer or advice. The preview above is blurred and illustrative. How this is calculated
Weighing a Generate Biomedicines offer?
Upload the offer letter to see what the equity is approximately worth at today's estimated price. No account needed.
X-ray an offerLeaving Generate Biomedicines? Mind the window.
If you hold options, leaving usually starts a post-termination exercise clock, often 90 days. Miss it and vested options can expire worthless; exercise blindly and you may owe real money (including possible AMT) on shares you can't yet sell. Neither panic nor autopilot is a plan. Knowing your window, your exercise cost, and the current estimated price is.
Generate Biomedicines in the last 12 months
- 1 funding round
Covered by 4 distinct publications since 2026-02-23.
Generate Biomedicines news timeline
- Drug developer Generate Biomedicines raises $400 million in US IPO2026-02-27Funding roundreuters.com
- Health Sector Faces Turbulence Amid Market Debuts and Vaccine Innovations2026-03-01devdiscourse.com
- Health News Highlights: IPOs, Trials, and Changes in Health Sector2026-03-01devdiscourse.com
- Volatile Debuts and Health Innovations: Unfolding Stories from the Health Sector2026-02-28devdiscourse.com
- Volatile Market Shakes Biomedicine Debuts and Global Health Initiatives2026-02-28devdiscourse.com
- Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer2026-02-27marketscreener.com
- Generate Biomedicines Faces Rocky Nasdaq Debut as Shares Dip2026-02-27devdiscourse.com
- Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut2026-02-27marketscreener.com
- Flagship-backed Generate Biomedicines seeks $425 million in IPO2026-02-23bostonglobe.com
- Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO2026-02-23reuters.com
Generate Biomedicines equity, answered plainly
Is Generate Biomedicines a public company?
No. Generate Biomedicines is privately held, which is exactly why its share price doesn't show up in your brokerage app. Its shares still change hands between eligible buyers and sellers on the secondary market, producing an observable estimated price.
What is Generate Biomedicines' stock price?
Generate Biomedicines has an observed estimated share price from secondary-market activity, updated as new data is observed. Its observed price history runs back to 2024-06-18. ExitCue members see the current estimate and its full history free, along with what their own grants are approximately worth at that price.
Can you sell Generate Biomedicines stock before an IPO?
Sometimes. Private-share sales depend on Generate Biomedicines' transfer restrictions, rights of first refusal, and whether the company runs tender offers or permits secondary sales. Your grant documents and the company's policies govern, but "hard to sell today" is not the same as "worth zero."
What happens to my Generate Biomedicines options if I leave?
Most option grants have a post-termination exercise window, commonly 90 days, sometimes longer, after which unexercised options expire worthless. The exact terms are in your grant documents. ExitCue reads those documents, tracks the deadline, and reminds you before the window closes.
How much is my Generate Biomedicines equity worth?
Multiply what you hold by the estimated share price, separating vested from unvested, and netting out strike prices for options. That's precisely the arithmetic ExitCue does for you, continuously, at the current observed estimate. It's an educational estimate, not a guarantee, and a far better anchor than the $0 the internet suggests.
What's the difference between Generate Biomedicines' 409A valuation and what its shares trade at?
The 409A is a tax-compliance appraisal, usually conservative, used to set option strike prices. Secondary-market pricing reflects what buyers and sellers actually agree to. The two frequently differ, which is why evaluating an offer on the 409A alone undersells (or oversells) it.
When will Generate Biomedicines IPO?
Unless Generate Biomedicines has publicly announced a listing, nobody knows, including the people who sound confident on forums. The practical upside of secondary markets is that you don't have to wait for an IPO to know approximately what the shares trade at.
Do my unvested Generate Biomedicines RSUs count for anything?
Unvested equity isn't yours yet, but it has an estimable value and a schedule. Seeing vested and unvested value separately, in dollars at the current estimated price, turns "some RSUs" into a number you can plan around.
General educational information, not advice about your specific situation. Grant terms vary; your documents govern.
Work out what your Generate Biomedicines equity is worth
These calculators take your own numbers and need no account.
- Option exercise costShares times strike: what exercising would cost, plus the estimated spread from your own value estimate.
- Vesting scheduleYour upcoming vest dates and cumulative vested shares from your start date, cliff, length, and frequency.
- Private stock scenarioEstimated value of your equity at low, mid, and high per-share scenarios you choose yourself.
New to this? Learn explains grant types, vesting and cliffs, and where an estimated share price comes from — in plain language.
Other private companies with observed prices
Company logos provided by Brandfetch.